News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


MDS to produce brain cancer drug


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.ottawabusinessjournal.com/285900316505144.php

Posted on: 04/21/2006

MDS to produce brain cancer drug

News Story

By Ottawa Business Journal Staff Wed, Apr 19, 2006 10:00 AM EST

MDS Nordion has signed a three-year contract with Bradmer Pharmaceuticals for the development and clinical trial supply of Neuradiab, an antibody used to treat the most common and deadly form of brain cancer.

"We are pleased that our world-class facilities, wealth of expertise and dedication to bringing products to market quickly will contribute to Neuradiab's development and its potential success," says MDS Nordion president Steve West.

Neuradiab is in clinical trials. It has been proven to be safe and effective in delivering tumor-killing radiation specifically to residual brain tumor cells following surgery, with minimal impact on the surrounding brain tissue.

"In six completed clinical trials involving over 160 cancer patients, Neuradiab has demonstrated a significant survival benefit over historical controls," says Dr. Mark Rogers, CEO of Bradmer Pharmaceuticals.

"This new agreement is an important step in our preparation for a planned multi-centre clinical trial for Neuradiab. We chose MDS Nordion based on their experience and standards of quality in developing and producing radiotherapeutics."

Neuradiab was developed at Duke University Medical Center in North Carolina.




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740